Project Grant R01AG097508
Award Date 1/1/26
Completion Date 12/31/30
Dollars Obligated $437K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- The National Institutes of Health's National Institute on Aging awarded the University of Wyoming a $4,510,756 project grant under the Aging Research program (CFDA 93.866) to investigate the impact of TAR DNA-binding protein 43 (TDP-43) loss on prefrontal neural activity and circuitry. The three-year award beginning September 2022 will support research using mouse models, human pluripotent stem cell-derived cortical neurons, and patient brain tissues to determine how TDP-43 loss leads to...
- The U.S. National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Adeptrix Corp a $499,940 Project Grant on September 11, 2025 to develop TAUTRACE, an ultrasensitive immunoassay platform capable of quantifying distinct molecular forms of the tau protein biomarker in cerebrospinal fluid and plasma down to femtogram/milliliter concentrations. This novel technology aims to enable more sensitive detection and measurement of tau proteoforms, which are...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $638,682 to the University of Arizona to investigate the role of the protein TDP-43 and its liquid-liquid phase separation (LLPS) in regulating mitochondrial function and their contribution to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease. The project aims to use cell and animal models to elucidate the...
- This $500,000 Project Grant was awarded on August 1, 2025 by the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, under the Aging Research federal grant program (CFDA 93.866). The grant is being used by T-Neuro Inc. in Albuquerque, NM to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease. The research aims to identify features upstream of...
- The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $442,750 to Case Western Reserve University to develop synthetic replicas of TDP-43 filaments associated with frontotemporal dementia and amyotrophic lateral sclerosis. The goal is to establish methods for generating in-vitro amyloid fibrils with structures identical to brain-derived TDP-43 filaments, which would enable further mechanistic studies and the...
- This $6,720,148 federal project grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop short RNA therapeutics that combat TDP-43 proteinopathy, which is a key pathological feature of several devastating neurodegenerative disorders including Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, and chronic traumatic encephalopathy. The project will establish methods to prevent and reverse the aberrant phase transitions of TDP-43, a...
- The University of Alabama at Birmingham (UAB) received a $816,750 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant, titled "POLY(ADP-RIBOSE)-DEPENDENT TDP-43 PATHOLOGY IN OXIDATIVE STRESS (R21)," aims to study the mechanisms by which the TDP-43 protein accumulates in the cytoplasm of neurons under oxidative stress conditions, which is a key pathological process in frontotemporal dementia (FTD) and other...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Redwood Neuro Inc. a $506,061 project grant to develop the SIMOLISA platform, an innovative and affordable immunoassay technology designed to enhance the detection of critical Alzheimer's disease (AD) biomarkers such as p-tau proteins and b-amyloid. The SIMOLISA platform aims to democratize early detection and longitudinal monitoring of AD by delivering advanced biomarker analysis...
- This $603,031 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Northwestern University supports a 1-year research study on the clinical, cellular, and pathological features of comorbid Alzheimer's disease and TDP-43 proteinopathies in elderly patients with amnestic dementia. The key objectives are to: 1) identify the shared versus distinct clinical, neuropsychological, and psychiatric characteristics of this condition; 2) determine the cellular...